Cargando…

2769. Treatment of Hypermutator Pseudomonas aeruginosa Induces Multidrug Resistance but Can Be Targeted by Combination Therapy

BACKGROUND: Up to 60% of Pseudomonas aeruginosa (Pa) strains isolated from human chronic lung infections lack an active DNA mismatch repair (MMR) system, resulting in a hypermutator phenotype. Hypermutator Pa isolates are associated with enhanced multidrug resistance and treatment failure, and treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Kalen M, Wimley, William C, Bojanowski, Christine M, Pursell, Zachary F, Morici, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677162/
http://dx.doi.org/10.1093/ofid/ofad500.2380
_version_ 1785150065014210560
author Hall, Kalen M
Wimley, William C
Bojanowski, Christine M
Pursell, Zachary F
Morici, Lisa
author_facet Hall, Kalen M
Wimley, William C
Bojanowski, Christine M
Pursell, Zachary F
Morici, Lisa
author_sort Hall, Kalen M
collection PubMed
description BACKGROUND: Up to 60% of Pseudomonas aeruginosa (Pa) strains isolated from human chronic lung infections lack an active DNA mismatch repair (MMR) system, resulting in a hypermutator phenotype. Hypermutator Pa isolates are associated with enhanced multidrug resistance and treatment failure, and treatments targeting hypermutators are not available. Although hypermutation has been shown to catalyze drug resistance acquisition, it is unclear how treatment of hypermutator Pa influences the development of multidrug resistance. METHODS: Here, we performed in vitro adaptive evolution of hypermutator Pa under different antibiotic conditions to assess if treatment of hypermutator Pa induces multidrug resistance acquisition via repeated selection for specific resistance-conferring mutations. We serially exposed hypermutator Pa and wild type Pa to four different antibiotics representing three drug classes, and subsequently tested evolved lineages against a panel of six non-treatment antibiotics from varying classes. RESULTS: We observed that hypermutator Pa acquired levels of resistance above clinical breakpoints (defined by Clinical and Laboratory Standards Institute) to all antibiotics tested faster than wild type Pa. Antibiotic treatment of hypermutator Pa selectively induced multidrug resistance acquisition but was irrespective of drug class. Using whole genome sequencing of resistant lineages, we found that treatment-induced multidrug resistance acquisition was determined by shared mechanisms of resistance rather than shared cell target. We subsequently tested combination therapies requiring independent and exclusive mechanisms of resistance and found that combined aztreonam/colistin effectively eliminated multidrug resistance acquisition in hypermutator Pa. Currently, we are testing this combination therapy on 14 Pa isolates (with 4 hypermutator and 10 wild type) from cystic fibrosis patients. CONCLUSION: Our results shed light on how hypermutator Pa may acquire multidrug resistance within the host and suggest that combination therapies that require independent mechanisms of resistance could potentially reduce emergence of multidrug resistance in hypermutator Pa, providing a viable therapeutic option. DISCLOSURES: Kalen M. Hall, B.S., B.A., Informuta: 1|Informuta: Ownership Interest|Informuta: Stocks/Bonds
format Online
Article
Text
id pubmed-10677162
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106771622023-11-27 2769. Treatment of Hypermutator Pseudomonas aeruginosa Induces Multidrug Resistance but Can Be Targeted by Combination Therapy Hall, Kalen M Wimley, William C Bojanowski, Christine M Pursell, Zachary F Morici, Lisa Open Forum Infect Dis Abstract BACKGROUND: Up to 60% of Pseudomonas aeruginosa (Pa) strains isolated from human chronic lung infections lack an active DNA mismatch repair (MMR) system, resulting in a hypermutator phenotype. Hypermutator Pa isolates are associated with enhanced multidrug resistance and treatment failure, and treatments targeting hypermutators are not available. Although hypermutation has been shown to catalyze drug resistance acquisition, it is unclear how treatment of hypermutator Pa influences the development of multidrug resistance. METHODS: Here, we performed in vitro adaptive evolution of hypermutator Pa under different antibiotic conditions to assess if treatment of hypermutator Pa induces multidrug resistance acquisition via repeated selection for specific resistance-conferring mutations. We serially exposed hypermutator Pa and wild type Pa to four different antibiotics representing three drug classes, and subsequently tested evolved lineages against a panel of six non-treatment antibiotics from varying classes. RESULTS: We observed that hypermutator Pa acquired levels of resistance above clinical breakpoints (defined by Clinical and Laboratory Standards Institute) to all antibiotics tested faster than wild type Pa. Antibiotic treatment of hypermutator Pa selectively induced multidrug resistance acquisition but was irrespective of drug class. Using whole genome sequencing of resistant lineages, we found that treatment-induced multidrug resistance acquisition was determined by shared mechanisms of resistance rather than shared cell target. We subsequently tested combination therapies requiring independent and exclusive mechanisms of resistance and found that combined aztreonam/colistin effectively eliminated multidrug resistance acquisition in hypermutator Pa. Currently, we are testing this combination therapy on 14 Pa isolates (with 4 hypermutator and 10 wild type) from cystic fibrosis patients. CONCLUSION: Our results shed light on how hypermutator Pa may acquire multidrug resistance within the host and suggest that combination therapies that require independent mechanisms of resistance could potentially reduce emergence of multidrug resistance in hypermutator Pa, providing a viable therapeutic option. DISCLOSURES: Kalen M. Hall, B.S., B.A., Informuta: 1|Informuta: Ownership Interest|Informuta: Stocks/Bonds Oxford University Press 2023-11-27 /pmc/articles/PMC10677162/ http://dx.doi.org/10.1093/ofid/ofad500.2380 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Hall, Kalen M
Wimley, William C
Bojanowski, Christine M
Pursell, Zachary F
Morici, Lisa
2769. Treatment of Hypermutator Pseudomonas aeruginosa Induces Multidrug Resistance but Can Be Targeted by Combination Therapy
title 2769. Treatment of Hypermutator Pseudomonas aeruginosa Induces Multidrug Resistance but Can Be Targeted by Combination Therapy
title_full 2769. Treatment of Hypermutator Pseudomonas aeruginosa Induces Multidrug Resistance but Can Be Targeted by Combination Therapy
title_fullStr 2769. Treatment of Hypermutator Pseudomonas aeruginosa Induces Multidrug Resistance but Can Be Targeted by Combination Therapy
title_full_unstemmed 2769. Treatment of Hypermutator Pseudomonas aeruginosa Induces Multidrug Resistance but Can Be Targeted by Combination Therapy
title_short 2769. Treatment of Hypermutator Pseudomonas aeruginosa Induces Multidrug Resistance but Can Be Targeted by Combination Therapy
title_sort 2769. treatment of hypermutator pseudomonas aeruginosa induces multidrug resistance but can be targeted by combination therapy
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677162/
http://dx.doi.org/10.1093/ofid/ofad500.2380
work_keys_str_mv AT hallkalenm 2769treatmentofhypermutatorpseudomonasaeruginosainducesmultidrugresistancebutcanbetargetedbycombinationtherapy
AT wimleywilliamc 2769treatmentofhypermutatorpseudomonasaeruginosainducesmultidrugresistancebutcanbetargetedbycombinationtherapy
AT bojanowskichristinem 2769treatmentofhypermutatorpseudomonasaeruginosainducesmultidrugresistancebutcanbetargetedbycombinationtherapy
AT pursellzacharyf 2769treatmentofhypermutatorpseudomonasaeruginosainducesmultidrugresistancebutcanbetargetedbycombinationtherapy
AT moricilisa 2769treatmentofhypermutatorpseudomonasaeruginosainducesmultidrugresistancebutcanbetargetedbycombinationtherapy